MedTrace Logo

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

NCT05921591 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-09-28

No results posted yet for this study

Summary

The purpose of this clinical study is to assess the safety, tolerability and pharmacokinetics of repeat doses of IRL201104 given to healthy volunteers.

Conditions

  • Healthy Volunteer

Interventions

DRUG

IRL201104

Lyophilised powder for reconstitution for IV dosing

DRUG

Placebo

Matching placebo for IRL201104

Sponsors & Collaborators

  • Revolo Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Anoshie Ratnayake, MD, MPH · Revolo Biotherapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-26
Primary Completion
2023-09-12
Completion
2023-09-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05921591 on ClinicalTrials.gov